ReviewFrontiers in cellular and infection microbiology2026
Therapeutic, preventive, and pathogenetic advances in viral hepatitis.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral hepatitis and associated liver injury represent a major global public health concern, capable of progressing to chronic liver disease, cirrhosis, and hepatocellular carcinoma. This review systematically summarizes classic hepatotropic viruses-including hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis A virus (HAV)-as well as atypical liver-injury pathogens such as hepatitis E virus (HEV), hepatitis D virus (HDV), human cytomegalovirus (HCMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), and yellow fever virus, with respect to their molecular biological characteristics, global epidemiological profiles, infection and pathogenic mechanisms, and strategies for diagnosis, treatment, and prevention. Particular emphasis is placed on the genomic architecture and replication cycles of these viruses, host immune responses and viral evasion strategies, key molecular events driving disease progression, and recent advances and remaining challenges in vaccination, direct-acting antiviral therapy, and public health interventions. By integrating evidence across multiple pathogens, this review aims to provide a systematic theoretical reference for the precise prevention and control of viral hepatitis and associated liver injury, as well as for the optimization of clinical diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.